title: Immune response induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B subunit.
abstract: The pentameric form of the cholera toxin B subunit (CTB) is known to be a strong mucosal adjuvant and stimulates antigen-specific secretory immunoglobulin A (IgA) and systemic antibody responses to antigens when given by mucosal routes. To deliver CTB for prolonged periods of time to the respiratory mucosa, we constructed a Mycobacterium bovis bacillus Calmette-Guérin (BCG) strain that produces and secretes assembled pentameric CTB. Mice immunized intranasally (i.n.) with recombinant BCG (rBCG) developed a stronger anti-BCG IgA response in bronchoalveolar lavage fluids (BALF) than mice immunized with nonrecombinant BCG. The total IgA response in the BALF of mice immunized with rBCG was also stronger than that in BALF of mice immunized with the nonrecombinant strain. The induction of IgA was well correlated with an increased production of transforming growth factor beta1. Simultaneous administration of intraperitoneally delivered ovalbumin and of i.n. delivered CTB-producing BCG induced a long-lasting ovalbumin-specific mucosal IgA response as well as a systemic IgG response, both of which were significantly higher than those in mice immunized with nonrecombinant BCG together with ovalbumin. These results suggest that the CTB-producing BCG may be a powerful adjuvant to be considered for future mucosal vaccine development.
authors.affiliation: Laboratoire de Microbiologie Génétique et Moléculaire, INSERM U447, IBL, Institut Pasteur de Lille, F-59019 Lille, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Biet
authors.forename: Laurent
authors.initials: L
authors.lastname: Kremer
authors.forename: Isabelle
authors.initials: I
authors.lastname: Wolowczuk
authors.forename: Myriam
authors.initials: M
authors.lastname: Delacre
authors.forename: Camille
authors.initials: C
authors.lastname: Locht
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000281:Administration, Intranasal; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D002772:Cholera Toxin / Q000008:administration & dosage* / Q000096:biosynthesis*; D007114:Immunization; D007070:Immunoglobulin A / Q000096:biosynthesis; D009163:Mycobacterium bovis / Q000235:genetics / Q000276:immunology*; D010047:Ovalbumin / Q000276:immunology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000502:physiology; D053773:Transforming Growth Factor beta1; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D014614:Vaccines, Synthetic; D010047:Ovalbumin; D002772:Cholera Toxin